AGING CELL:阿格列汀可改善高脂饮食对存活和健康的影响

2019-01-29 海北 MedSci原创

在过去的30年中,全世界超重和肥胖个体的数量急剧增加,导致肥胖相关健康问题爆发,这与发病率和死亡率的增加相关。

在过去的30年中,全世界超重和肥胖个体的数量急剧增加,导致肥胖相关健康问题爆发,这与发病率和死亡率的增加相关。肥胖患者表现出许多加速衰老的表型,例如血管疾病,糖尿病高血压,血脂异常,非酒精性脂肪肝和炎性疾病,所有这些都会导致寿命的缩短。

由于这些原因,研究人员正在积极地寻求改善与肥胖相关的健康问题的方法,以延长寿命。

阿格列汀是治疗2型糖尿病患者的常用处方药。最近,研究人员发现,长期使用阿格列汀(饮食中含0.03%w / w)可改善高脂饮食小鼠的存活率和健康状况。阿格列汀干预具有与长寿相关的有益效果,包括增加的胰岛素敏感性,减弱的功能性下降,器官病理学减少,线粒体功能保持,和氧化应激减少。此外,研究人员提出自噬激活作为这些有益效果的潜在机制。

研究人员得出结论,阿格列汀干预可被视为改善肥胖和超重个体的寿命和健康的潜在策略。


原始出处:

Biao Zhu et al. Alogliptin improves survival and health of mice on a high‐fat diet. AGING CELL, 2019; doi: https://doi.org/10.1111/acel.12883


本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961395, encodeId=e3b9196139501, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Oct 22 14:32:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871118, encodeId=95d518e1118ef, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 27 19:32:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574634, encodeId=6c0915e4634fc, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597017, encodeId=b116159e017c5, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-10-22 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961395, encodeId=e3b9196139501, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Oct 22 14:32:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871118, encodeId=95d518e1118ef, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 27 19:32:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574634, encodeId=6c0915e4634fc, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597017, encodeId=b116159e017c5, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961395, encodeId=e3b9196139501, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Oct 22 14:32:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871118, encodeId=95d518e1118ef, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 27 19:32:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574634, encodeId=6c0915e4634fc, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597017, encodeId=b116159e017c5, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 pcw111
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961395, encodeId=e3b9196139501, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Oct 22 14:32:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871118, encodeId=95d518e1118ef, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 27 19:32:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574634, encodeId=6c0915e4634fc, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597017, encodeId=b116159e017c5, content=<a href='/topic/show?id=31809e853e9' target=_blank style='color:#2F92EE;'>#阿格列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97853, encryptionId=31809e853e9, topicName=阿格列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20c618457863, createdName=lizhou0210, createdTime=Thu Jan 31 06:32:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]

相关资讯

NEJM:阿格列汀能安全用于T2DM患者合并心血管高危风险(EXAMINE研究)

   对于T2DM患者合并心血管高危风险(15-90天内有急性心梗和不稳定性心绞痛住院患者),加用阿格列汀(alogliptin)或安慰剂治疗,发现alogliptin并不增加主要大血管事件,对于糖尿病合并心血管高危风险患者是安全的。这是EXAMINE研究的核心结果。结果将于ESC荷兰阿姆斯特丹当地时间9月2日上午11:18公布;NEJM 新英格兰杂志将同步于ESC期间发表。 原始出处

Lancet:阿格列汀不增加2型糖尿病心衰风险(EXAMINE 试验)

先前有一项EXAMINE研究证明DPP-4抑制剂阿格列汀与安慰剂相比,在增加T2DM主要心血管事件风险中呈非劣性。而另一项报道称使用DPP-4抑制剂可能增加住院患者心衰风险,令人担忧。因此,近来有研究进行另一项EXAMINE评估阿格列汀对入院患者发生心衰的影响。 试验中,研究者将已接受糖尿病标准化和心血管疾病预防治疗的2型糖尿病合并ACS患者,随机分为阿格列汀或安慰剂治疗组。 预先设定的评价终

Diabetes Care:阿格列汀可减缓2型糖尿病的颈动脉粥样硬化进展(SPEAD-A)

研究者进行了一项研究,调查二肽基肽酶-4DPP-4)抑制剂阿格列汀在2型糖尿病患者动脉粥样硬化进展中的作用。该多中心前瞻性随机盲法研究纳入了341名2型糖尿病患者,既往没有心血管疾病史,将其随机分为阿格列汀治疗组(n=172)和常规处理对照组(n=169)。以24个月的治疗期间,通过颈动脉超声检查观察到的动脉内膜中层厚度 (IMT)变化为结局指标。研究数据显示,阿格列汀治疗组比对照组降低血糖效果更

Diabetes Obes Metab:基线HbA1c水平和低血糖与不良心血管事件有多大关联?

2017年5月,发表在《Diabetes Obes Metab》的一项研究调查了糖化血红蛋白(HbA1c)与低血糖与主要不良心血管事件(MACE)风险之间的关联。研究结果显示,基线HbA1c水平或治疗1个月后HbA1c水平与MACE水平无关。低血糖事件和严重低血糖与MACE相关。

ADA 2015:阿格列汀未增加ACS患者心血管事件(EXAMINE试验)

EXAMINE试验中有关心肌缺血事件和心血管住院率的所有数据以口头报告的形式公布。EXAMINE试验评估了近期发生急性冠脉综合征的2型糖尿病患者在接受DPP-4抑制剂阿格列汀后的心血管事件。结果显示,在EXAMINE试验人群中,心肌梗死及不稳定型心绞痛、冠脉重建、心血管事件住院以及这些缺血性事件构成的复合终点的发生率普遍较高,尤其是心血管事件住院率及冠脉重建。但以上心肌缺血事件在阿格列汀组和安慰剂

糖尿病新药进展!武田2型糖尿病复方药Inisync(阿格列汀/二甲双胍)获日本批准

日本制药巨头武田(Takeda)近日宣布,日本卫生劳动福利部(MHLW)已批准糖尿病复方新药Inisync复方片,用于2型糖尿病的治疗。Inisync复方片由固定剂量的Nesina(阿格列汀,alogliptin,25mg)和二甲双胍(500mg)组成,每日口服一次。此次批准,使Inisync成为日本市场唯一一种每日口服一次的DPP-4和二甲双胍复方药。 Inisync的获批,是基于与Nes